Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes

- December 20th, 2018

Lexicon Pharmaceuticals (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 (SGLT1) inhibitor in development for the treatment of diabetes. As quoted in the press release: “Results from our Phase 1 studies build on previously reported promising preclinical data for LX2761 and confirm the drug candidate’s … Continued

Lexicon Pharmaceuticals (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 (SGLT1) inhibitor in development for the treatment of diabetes.

As quoted in the press release:

“Results from our Phase 1 studies build on previously reported promising preclinical data for LX2761 and confirm the drug candidate’s unique preclinical profile as a potent, gastrointestinal tract-selective SGLT1 inhibitor,” said Praveen Tyle, Ph.D., executive vice president of Research and Development. “We are evaluating next steps for this compound and look forward to providing updates in the future.”

The Phase 1 clinical studies of LX2761 included a Phase 1a single ascending-dose study in healthy volunteers and patients with type 2 diabetes, and a Phase 1b multiple ascending-dose study in patients with type 2 diabetes.

The Phase 1a study involved 5 cohorts of healthy volunteers and 2 cohorts of patients with type 2 diabetes. Patients with type 2 diabetes were washed off metformin for 3 days prior to dosing. LX2761 demonstrated minimal absorption and no systemic effect, with no increase in urine glucose excretion from baseline. In addition, LX2761 reduced postprandial glucose in diabetic patients while increasing plasma levels of GLP-1. The most common adverse and dose-limiting event was diarrhea, consistent with the SGLT1mechanism of action due to reduced glucose absorption in the gut.

Click here to read the full press release.

Find out what experts are saying about the future of cannabis

 
Read our 2019 conference report today
 

Leave a Reply